Oral semaglutide 14 mg demonstrated superior reduction in risk of cardiovascular events in late-breaking SOUL trial presented at the American College of Cardiology
SOUL study showed Rybelsus® (semaglutide) tablets 14 mg reduced the risk of major adverse cardiovascular events (MACE) by 14% (ARR 2% absolute risk reduction at 3 years) vs placebo in